Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.83 |
| ▸ | BRD1 | O95696 | 1/20 | 0.62 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CCR4 | P51679 | 2/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722196 | 0.76 | BRPF1 (1.00) | BRD4BRD1BRPF1PKMCREBBP | |
| SCHEMBL14721412 | 0.73 | BRD4 (0.67) | BRD4BRD1BRPF1PKMCREBBP | |
| SCHEMBL28666833 | 0.72 | BRD4 (0.60) | BRD4BRD1BRPF1PKMCREBBP | |
| SCHEMBL7569855 | 0.71 | SLC22A12 (0.58) | BRD4BRD1BRPF1PKMCREBBP | |
| SCHEMBL7364604 | 0.71 | CA12 (0.59) | BRD4PKMSLC22A12 | |
| SCHEMBL29430449 | 0.71 | BRD4 (1.00) | BRD4CREBBP | |
| SCHEMBL14721611 | 0.71 | BRD4 (1.00) | BRD4CREBBP | |
| SCHEMBL14339623 | 0.71 | LMNA (0.55) | BRD4PKMPOLB | |
| SCHEMBL14757111 | 0.70 | BRD4 (0.62) | BRD4BRD1BRPF1PKMCREBBP | |
| SCHEMBL5305683 | 0.70 | LMNA (0.66) | BRD4PKMTP53SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRD1 3/4885BRPF1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.